The estimated Net Worth of Lucy Shapiro is at least $5.4 Milion dollars as of 22 January 2016. Lucy Shapiro owns over 101,666 units of Pacific Biosciences of California Inc stock worth over $170,799 and over the last 12 years he sold PACB stock worth over $5,123,966. In addition, he makes $108,333 as Independent Director at Pacific Biosciences of California Inc.
Lucy has made over 3 trades of the Pacific Biosciences of California Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 101,666 units of PACB stock worth $5,123,966 on 12 February 2021.
The largest trade he's ever made was selling 101,666 units of Pacific Biosciences of California Inc stock on 12 February 2021 worth over $5,123,966. On average, Lucy trades about 20,333 units every 123 days since 2012. As of 22 January 2016 he still owns at least 101,666 units of Pacific Biosciences of California Inc stock.
You can see the complete history of Lucy Shapiro stock trades at the bottom of the page.
Dr. Lucy Shapiro Ph.D. serves as Independent Director of the Company. Dr. Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University's School of Medicine, where she has been a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, Inc. which was acquired by Pfizer Inc. in 2016. In 2016 she founded a second anti-infectives company, Boragen, LLC. In 1989, Dr. Shapiro founded Stanford University's Department of Developmental Biology, and served as its Chairman from 1989 to 1997. Prior to that, Dr. Shapiro served as Chair of the Department of Microbiology and Immunology in the College of Physicians and Surgeons of Columbia University. She received a B.A. from Brooklyn College and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine. Dr. Shapiro has received numerous awards including the National Medal of Science. She has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the National Academy of Medicine for her work in the fields of molecular biology and microbiology. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006 and Anacor Pharmaceuticals, Inc. from 2001 to 2016. Dr. Shapiro was also a director of Gen-Probe, Inc. from 2008 to 2012. Shapiro possesses specific attributes that qualify her to serve as a member of our Board of Directors, including her extensive experience in the life sciences industry.
As the Independent Director of Pacific Biosciences of California Inc, the total compensation of Lucy Shapiro at Pacific Biosciences of California Inc is $108,333. There are 8 executives at Pacific Biosciences of California Inc getting paid more, with Michael Hunkapiller having the highest compensation of $859,188.
Lucy Shapiro is 79, he's been the Independent Director of Pacific Biosciences of California Inc since 2012. There are no older and 18 younger executives at Pacific Biosciences of California Inc.
Lucy's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025.
Over the last 14 years, insiders at Pacific Biosciences of California Inc have traded over $95,441,111 worth of Pacific Biosciences of California Inc stock and bought 2,252,330 units worth $6,097,136 . The most active insiders traders include Michael Hunkapiller, John F Milligan a Christian O Henry. On average, Pacific Biosciences of California Inc executives and independent directors trade stock every 44 days with the average trade being worth of $202,112. The most recent stock trade was executed by Jeff Eidel on 19 August 2024, trading 26,760 units of PACB stock currently worth $42,548.
pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.
Pacific Biosciences of California Inc executives and other stock owners filed with the SEC include: